Epidemiological studies have indicated that lung cancer arises as a consequence of exposure to smoking (Carbone, 1992) . More than 20 components of tobacco smoke have been shown to cause lung tumors in laboratory animals or humans (Hecht, 1999) . Although a number of experimental studies have evaluated the genotoxicity of typical tobacco smoking components, such as benzo[a]-pyrene (B[a]P) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), less attention has been paid to the overall effects of cigarette smoke. The whole-body exposure of A/J mice or p53 mutant A/J mice to tobacco smoke for 5 months, followed by 4 months of recovery in filtered air, increased both lung tumor incidence and multiplicity (Witschi et al., 1995; Witschi, 2000; D'Agostini et al., 2001; De Flora et al. 2003) .
Genetic alterations in K-ras, p53, and Ink4a/Arf are commonly found in human lung cancers, especially in human lung adenocarcinomas (Minna, 1993; You and Bergman, 1998) . Mutations in K-ras are found in nonsmall cell lung carcinomas (NSCLCs), predominantly in adenocarcinoma. The frequency of mutations ranges from 15 to 50% depending on the study material and the sensitivity of the assay used (Rodenhuis et al., 1988; Rodenhuis and Slebos, 1992) . Over 90% of the mutations that occurred in K-ras gene were in codon 12 in human NSCLCs (Rodenhuis and Slebos, 1990) . Activated K-ras has also been detected in spontaneously occurring and chemically induced mouse lung tumors (You et al., 1989; Herzog et al., 1993) . Loss of the wildtype K-ras allele promotes activation of K-ras mutationdriven lung carcinogenesis (Zhang et al., 2001 . The frequency of the occurrence of the activated K-ras gene depends upon the relative susceptibility of the mouse strain and the carcinogen treatment protocol used to induce tumors (You et al., 1989) . For example, spontaneous lung tumors were found in both codon 12 (60%) and codon 61 (30%) (You et al., 1989) . In contrast, 100% of the mutations in the K-ras gene detected in methylnitrosourea (MNU)-induced lung tumors and 93% of the mutations in the K-ras genes detected in B[a]P-induced lung tumors were in codon 12, whereas 90% of the mutations in the K-ras genes detected in ethyl carbamate-induced lung tumors were in codon 61. A recent report found that six of nine lung tumors from tobacco smoke-exposed mice contained Kras mutations in codon 61 (Witschi et al., 1995 (Witschi et al., , 2002 .
Mutations of the p53 gene are detectable in 50-70% of patients with lung cancer and are found in all histologic types (Chiba et al., 1990; Takahashi et al., 1991; Marchetti et al., 1993; Top et al., 1995; Wiethege et al., 1995) . Alterations of the p53 gene are found in different tumor stages and may even occur in premalignant stages, such as metaplasias and dysplasias (Sozzi et al., 1992; Fontanini et al., 1994) . The p53 mutation carriers in Li-Fraumeni syndrome families are at a significantly increased risk for lung cancer (Hwang et al., 2003) . Germline p53 mutation carriers who smoked had a 3.16-fold higher risk for lung cancer than the germline p53 mutation carriers who did not smoke. Similarly, a p53 transgenic mouse model on A/J background also exhibited a significant increase of lung tumor multiplicity when compared to the wild-type A/J mice after receiving chemical carcinogens B[a]P, NNK, or MNU (Zhang et al., 2000) . This mouse model appears to be relevant to the human disease, as point mutations or deletions in p53 are the most common genetic lesions in human cancer (Levine, 1997; Wang and Harris, 1997; Hursting et al., 2001) .
Inactivation of the p16 INK4a is also commonly seen in lung cancer Shapiro et al., 1995) . The Ink4a/Arf locus encodes two functionally distinct tumor suppressors, p16
INK4a and ARF (Kamb et al., 1994) . The p16
INK4a gene codes for an inhibitor of the cyclin D-cdk complex and thereby affects the Rb/E2F pathway and cell cycle progression (Serrano et al., 1993) . Mice with an Ink4a/Arf heterozygous deficiency significantly increased in lung tumor growth and progression (Zhang et al., 2002) .
The purpose of this study was to determine the effects of germline alterations in K-ras, p53, or Ink4a/Arf on tobacco smoke-induced lung tumorigenesis, and to identify the mutational spectrum of the K-ras oncogene in lung tumors from tobacco smoke-treated mutant A/J mice. A/J mice were obtained from the Jackson Laboratories (Bar Harbor, ME, USA). All the mice used in this study were housed in high-efficiency particulate arrest (HEPA)-filter-protected plastic cages with hardwood bedding and dust covers, in an environmentally controlled room (24711C, 12/12 h light/dark cycle). Animals were given Rodent Lab Chow (5001, Purina) and water ad libitum. Body weights were monitored monthly for the duration of the studies. The animal models used in this study are A/J, N8(A/J Â 129/ Sv-K-ras (Zhang et al., 2001; Wang et al., 2003) .
Detailed genotyping procedures were reported previously (Zhang et al., 2001; Wang et al., 2003) . The genotyping procedures for all three genes (K-ras, p53, and Ink4a/Arf) were repeated at least once for confirmation. Although each knockout or transgene was from a different genetic background, that is, C57BL/6 or 129Sv, they have been backcrossed to A/J through selected breeding to ensure the appropriateness of statistical comparison. In backcrossing these knockout or transgenic mice onto the A/J background, we used a selected breeding strategy that is also called 'speed congenics'. We have genotyped the progeny of each generation of backcrossing using B50 genetic markers across the whole genome to select the progeny with the least donor DNA for additional backcrossing. This would lead to the creation of a congenic strain with less than 0.5% contaminating donor genome unlinked to the locus of the knockout or transgene in a total of five generations of backcrosses. Thus, our lines of knockout or transgenic mice (N6, 8, or 10) should have B100% of the A/J genetic backgrounds after 6, 8, or 10 generations of backcrossing using selected breeding strategy, which would make the direct comparison between different groups of mice appropriate in this study.
The TE-10z cigarette-smoking machine was purchased from TEAGUE Enterprises (Davis, CA, USA). The 1RF4 Research cigarettes were purchased from Tobacco and Health Research Institute (University of Kentucky, Lexington, KY, USA). Before their use in the study, the cigarettes were kept in a standardized atmosphere humidified with a mixture of 70% glycerol and 30% water for 48 h. Smoke generated by the TE-10z cigarette-smoking machine is a mixture of cigarette sidestream (B90%) and mainstream smoke (B10%) with suspended particles (TSP) of 80-180 mg/m 3 . The cigarettes were smoked with standard puffs of 35 ml volume of 2 s duration (Teague et al., 1994) . The cages that contain the mice exposed to environmental tobacco smoke (ECS) were placed in a steel inhalation chamber. The position of the cages in the exposure chambers was rotated daily.
The treatment groups of 6-week-old mice with cigarette smoke are illustrated in Table 1 . Mice (6-week-old) were randomized into 10 groups based on Approximately equal numbers of males and females were used, with no significant difference in tumor multiplicity between the sexes. b P-value, tumor multiplicity in smoking groups (6-10) when compared to their corresponding control groups (1-5), nonparametric Kruskal-Wallis test Tobacco smoke-induced lung tumorigenesis Y Wang et al their genotypes. Mice in groups 1-5 were kept in filtered air (sham-exposed) for 11 months as control mice. Mice in groups 6-10 were exposed whole-body to ECS 6 h a day, 5 days a week for 6 months followed by 5 months of recovery in filtered air. During the bioassay, all of the animals were observed daily for clinical signs of ill health and weighed individually twice a month for the duration of the study. After 11 months, all of the surviving sham-exposed mice and all of the mice exposed to ECS for 6 months followed by 5 months of recovery in filtered air were terminated by CO 2 asphyxiation. Selected lung tumors were removed from the surrounding normal tissues. Portions of the tumor tissues and normal tissues were flash frozen at À801C. The remaining lungs were fixed in Telleninsky's solution (90% ethanol (70% v/v), 5% glacial acetic acid, 5% formalin (10% v/v buffered formalin)) overnight, and then stored in 70% ethanol until paraffin embedding. Lung tumors were evaluated by counting tumor multiplicity under a stereomicroscope. Since the counts of lung tumors did not follow well normal distribution, nor did any common transformations, we used the nonparametric Kruskal-Wallis test to determine the difference in the number of pulmonary tumors per mouse between air control and groups exposed whole-body to ECS for each genotype. Approximate P-values derived from w 2 distribution with 1 degree of freedom are presented in Table 1 .
As shown in Table 1 , mice in groups 1-5 were kept in filtered air (sham-exposed). Mice in groups 6-10 were exposed whole-body to ECS (ECS-exposed). Exposure to ECS produced a moderate decrease (10%) of body weight as compared with control mice (data not shown). This was observed in the first month after ECS exposure and continued until the end of ECS exposure. The body weight recovered to normal body weight ranges soon after the discontinuation of ECS exposure. Animals were killed 11 months after initial exposure (6 months ECS or sham followed by 5 months of recovery in filtered air). In the sham-exposed groups, a low incidence of lung tumors, ranging from 0.9 to 1.3 tumors/mouse, was observed. And, there was no significant difference in tumor multiplicity in Ink4a/ Arf
þ /À aircontrol mice as compared to the wild-type air-control mice. In contrast, a significant increase in lung tumor multiplicity was found in all ECS-exposed groups regardless of their specific genotypes, except wild-type mice (group 6). The air-control wild-type mice developed 0.9 tumors/mouse and the ECS-exposed wild-type mice developed an average of 1.6 tumors/mouse (P-value ¼ 0.0861). ECS-exposed K-ras
, and p53 þ /À Ink4a/Arf þ /À mice developed an average of 1.8, 1.7, 2.0, and 3.2 tumors/mouse, respectively. On the other hand, the air-control K-ras
, and p53 þ /À Ink4a/ Arf þ /À mice developed an average of 0.9, 0.9, 1.1, and 1.3 tumors/mouse, respectively. The differences are significant with P-value ¼ 0.0128 for K-ras
þ /À mice, and P-value ¼ 0.0042
There was no genderspecific effect since no significant difference in tumor multiplicity between the genders was seen.
Interestingly, p53
þ /À Ink4a/Arf þ /À mice carrying a mutant p53 transgene (Val135) with Ink4a/Arf heterozygous deletion have an average of tumor multiplicity at 3.274.1 in smoked mice and 1.371.2 in control mice. The increase is B2.5-fold. However, either p53 þ /À or Ink4a/Arf þ /À alone would only enhance lung multiplicity by B1.8-fold when exposed to ECS (2.071.4 vs 1.170.8 for p53
þ /À mice and 1.771.2 vs 0.971.2 for Ink4a/Arf þ /À mice), indicating an increased effect in the presence of a mutant p53 transgene and the Ink4A/Arf deletion. In addition, approximately 30% of the lung tumors from mice with a p53 mutation and deletion of Ink4A/Arf (p53
) were lung adenocarcinomas. In contrast, lung adenocarcinomas were not seen in any of the lung tumors from the wild-type mice and were seen in less than 10% of the lung tumors from either p53 transgenic mice or Ink4a/Arf heterozygous deficient mice. Figure 1 shows the light photomicrographs of lung tumors (adenoma vs carcinoma) from mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. As shown in Figure 1b 
Ink4a/Arf
þ /À mice. K-ras mutations were identified by utilizing polymerase chain reaction (PCR) technique to amplify the first and second exons of the K-ras gene followed by sequence analysis of the amplified product using the procedures and primers reported previously (You et al., 1992) . Lung tumors obtained from selected groups (Table 1) were analysed for mutations in the K-ras gene in codons 12, 13, and 61. The sequences were determined and the results (representative mutations) are shown in Figure 2 . Sequence analysis indicated that mutations had occurred at either codon 12 or 61 in tumors from both the sham-exposed and ECS-exposed animals ( Table 2 ). Of the 26 lung tumors from shamexposed mice (eight from A/J, 10 from K-ras þ /À , and eight from p53 þ /À mice), 16 were found to contain K-ras mutations. In all, 10 of 16 tumors (62%) from the shamexposed mice with 12 mutations (two tumors had double mutations) were found in codon 12 of the K-ras gene. The mutations were GC-TA transversions (two at the first position and eight at the second position) and GC-AT transitions (one at the first position and two at the second position). Three of 16 tumors (18%) with three mutations were found in codon 13 with one GC-AT transition at the second position and two GC-CG transversions at the first position. Finally, three of 16 tumors (18%) with three mutations were found in codon 61 with two AT-TA transversions at the second position and one AT-TA transversion at the third position. For lung tumors from ECS-exposed mice, we used a total of 30 lung tumors with 10 tumors from A/J mice, 10 from K-ras þ /À mice, and 10 from p53 þ /À mice. Out of 30 lung tumors from ECS-exposed mice, 25 were found to contain K-ras mutations. In all, 15 of 25 (60%) tumors with 18 mutations (three tumors had double mutations) were found in codon 12 of the K-ras gene of tumors from the sham-exposed mice. The mutations were GC-TA transversions (six at the first position and eight at the second position), GC-AT transitions (one at the first position and two at the second position), and GC-CG transversions (two at the first position). Two of 25 tumors (8%) with two mutations were found in codon 13 with two GC-CG transversions at the first position. Finally, eight of 25 tumors (32%) with eight mutations were found in codon 61 with one AT-TA transversion at the second position, one AT-GC transition at the second position, one AT-CG transversion at the third position, and five AT-TA transversions at the third position.
As shown in Table 2 , the mutation spectra in tumors from both the sham-exposed and ECS-exposed animals were similar with 62% of the sham-exposed tumors and 83% of the ECS-exposed tumors containing K-ras mutations. There was no significant difference in the codon distribution of the mutations between shamexposed and ECS-exposed tumors, with 62% codon 12, 18% codon 13, and 18% codon 61 in the sham-exposed tumors vs 60% codon 12, 8% codon 13, and 32% codon 61 in the ECS-exposed mice. In addition, three double mutations at codon 12, GGT (Gly)-TTT (Phe), ATT (Ile), and CTT (Leu), were identified in the K-ras gene in both sham-exposed tumors (two of the three mutations) and the ECS-exposed tumors (all three mutations) (Figure 2 ).
The present study systematically investigated whether mice carrying alterations in K-ras, p53, or Ink4a/Arf might be particularly susceptible to tobacco smokeinduced lung tumorigenesis. As shown in Table 1 , a significant increase of lung tumor multiplicity was induced in K-ras, p53, and/or Ink4a/Arf mutant mice compared to their respective sham control mice. As described by Witschi et al. (2002) , whole-body exposure of A/J mice to ECS for 5 months, followed by 4 months of recovery in filtered air, significantly increased lung tumor multiplicity. This observation was confirmed by another laboratory by exposing A/J mice to ECS for 5 months followed by 4 months of recovery in air (De Flora et al., 2003) . Recently, we found that lung tumor multiplicity in p53 mutant mice was increased when mice were exposed whole-body to ECS for 5 months followed by 4.5 months of recovery in filtered air. With an average 3.274.1 tumors/mouse in p53
þ /À mice that can be induced by ECS, this mouse lung tumor model may be more feasible than wild-type mice with an average 1.671.0 tumors/mouse for chemoprevention and chemotherapy studies. Large standard deviation in our data could be due to small sample sizes. In order to reduce the standard deviation, a bigger number of mice are recommended to use in the future studies.
The double mutant (p53/p16) transgenic model might be a more relevant lung tumor model than the commonly used A/J mouse for tobacco-smoke studies. Mutations in K-ras are found in more than 40% of human lung adenocarcinomas (Rodenhuis et al., 1988; Rodenhuis and Slebos, 1992) . p53 Mutations have been found in 50-80% of sporadic lung cancers, indicating that p53 plays a crucial role in the development of human lung cancer (Chiba et al., 1990) . A recent study by Hwang et al. (2003) indicated that, in humans, the p53 germline mutation carriers (equivalent to our p53 dominant-negative mutant p53 mice) have significantly increased risk for lung cancer of a variety of histological types. Hwang et al. (2003) found that the carriers who smoked had a 3.16-fold higher risk for lung cancer than the mutation carriers who did not smoke. p16
INK4a is another tumor suppressor that is frequently inactivated in human lung cancer Hamada et al., 1998; Gazzeri et al., 1998) .
An interesting finding of this study is an additive effect between the presence of a mutant p53 transgene and the Ink4A/Arf deletion during tobacco smokeinduced lung tumorigenesis. Mice with p53 mutation and Ink4a/Arf heterozygous deficiency exhibited 2.5-fold increase in tumor multiplicity, while either p53
þ /À alone would only enhance lung multiplicity 1.8-fold when exposed to ECS. This result is consistent with our earlier observation of synergistic effect in carcinogen-induced lung tumor progression in mice with p53 mutation and deletion of Ink4a/Arf (p53 . There have been reports on interactions between alterations of the p16 INK4A gene and the p53 gene in tumor development (Kinoshita et al., 1996; Bardeesy et al., 2002) . While examining NSCLC in humans, proliferative activity was considerably higher in p53-mutant tumors than in p53-normal tumors and loss of p16 INK4a expression was associated with a further increase in proliferative activity in the p53-mutant tumors, but not with proliferative activity in the p53-negative tumors (Kinoshita et al., 1996) . Bardeesy et al. (2002) INK4a and mutant-p53, as the TGFa animals heterozygous for both the Ink4a/Arf and the p53 mutation showed a dramatically increased incidence of serous cystadenoma than those with heterozygosity at either locus alone.
The present study found that the majority of the Kras mutations were in codons 12 and 13 (81 and 68% in smoking and control groups, respectively) ( Table 2) . We also identified three double mutations at codon 12, which have not been previously reported. These results are consistent with previous studies on spontaneously occurring lung tumors (60% in codon 12 and 30% in codon 61 K-ras mutations) and are different from lung tumors induced by tobacco-specific carcinogens, for example, NNK or B[a]P in which mutations are almost exclusively in codon 12 (You et al., 1989 (You et al., , 1992 Devereux et al., 1991; Chen et al., 1993; Ronai et al., 1993; Matzinger et al., 1995) . Our results are also consistent with those found in human studies, which show that 30-35% human adenocarcinomas with K-ras mutations, 90% are found in codon 12 (Slebos et al., 1991; Husgafvel-Pursiainen et al., 1993) . When comparing the mutation spectra in tumors from both the sham-exposed and ECS-exposed animals, we did not see a significant difference in the codon distribution of the mutations with 62% codon 12, 18% codon 13, and 18% codon 61 in the sham-exposed tumors vs 60% codon 12, 8% codon 13, and 32% codon 61 in the ECS-exposed tumors. This raises the possibility that tobacco smoke enhances lung tumorigenesis primarily through promoting spontaneously occurring Kras mutations. Our results are in contrast with previous reports, which found a shift in K-ras mutations in tobacco smoke-induced lung tumors from a relatively even distribution among codons 12/13 and 61 to mostly in codon 61 (Witschi et al., 1995) . Three possible explanations may account for the mostly codon 61 Kras spectrum in tobacco smoke-induced lung tumors (Witschi et al., 1995 (Witschi et al., , 2002 : (1) the number of tumors examined in their studies was relatively small (o10/ group); (2) the largest tumors were used for K-ras mutation analysis and may have biased the study by specifically examining those tumors most likely to harbor the codon 61 mutant allele; and (3) tobacco smoke may promote the outgrowth of spontaneously mutated lesions in the A/J lung already predisposed to develop K-ras mutations. The significant induction of lung tumors in this model exposed for roughly 1/5 of their expected lifetime is interesting since approximately 10-20% of long-term human smokers will develop lung cancer. In summary, we described two major findings in this study. First, we demonstrated that mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf were susceptible to tobacco smoke-induced lung tumorigenesis. Second, we found that the mutation spectrum in tumors from mice exposed to tobacco smoke was similar to that in tumors from air-control mice. We provided evidence that K-ras, p53, or p16
INK4a mutations play a role in tobacco smoke-induced lung carcinogenesis. The similarity of the mutation spectra in the K-ras oncogene observed in tobacco smoke-induced tumors, as compared to sham-exposed tumors, suggests that tobacco smoke enhances lung tumorigenesis primarily through promoting spontaneously occurring K-ras mutations.
